目的:对神经氨酸酶抑制剂(neuraminidase inhibitor,NAI)治疗流行性感冒(简称流感)有效性及安全性的系统评价/Meta分析(Systematic reviews/Meta analysis,SRs/MRs)进行再评价,以期为该药的临床应用提供循证依据.方法:系统检索中国知网(CNKI)、万方数据知识服务平台(Wanfang)、维普网(VIP)、中国生物医学文献服务系统(SinoMed)、PubMed、Embase、Cochrane Library、Web of Science数据库,收集NAI治疗流感的SRs/MRs,评价其原始研究质量,并分别采用AMSTAR-2量表及GRADE证据分级系统评价文献质量和证据质量.结果:共纳入11篇SRs/MRs,涉及78个结局指标.原始研究为高质量随机对照试验(randomized controlled trial,RCT),AMSTAR-2方法学质量评价为低级和极低级;GRADE证据质量评价显示,78个结局指标中级占10.3％,低级占53.8％,极低级占35.9％.结论:现有研究显示NAI治疗儿童、成人及老年人流感具有一定的疗效、安全性,但鉴于系统评价/Meta分析方法学质量及证据质量等级偏低,尚需开展更多高质量研究以获取高质量的研究结果去验证.
The Efficacy and Safety of Neuroaminidase Inhibitors for the Treatment of Influenza:An Overview of Systematic Reviews
Objective:To overview the systematic reviews about the efficacy and safety of neuraminidase inhibitor(NAI)for the treatment of seasonal influenza,the purpose is to provide factual recommendations for the clinical use of this medicine.Methods:CNKI,Wanfang Database,VIP,SinoMed,PubMed,Embase,Cochrane Library,and Web of Science were searched to collect the SRs/MRs of NAI in the treatment of influenza,evaluate the quality of its original research and the AMSTAR-2 tool and the GRADE system were used to assess the quality of the literature and the quality of evidence respectively.Results:11 SRs/MRs were finally included,covering 78 out-come measures.All original research conducted is of high-quality randomized controlled trials(RCTs).The methodological quality assess-ment using the AMSTAR-2 tool indicated predominantly very low and low quality.The GRADE evidence quality assessment showed that 10.3％of the 78 outcome measures were assessed as moderate grade,53.8％as low grade,and 35.9％as very low grade.Conclusion:Existing research suggests that NAI treatment has demonstrated certain efficacy and safetyin treating influenza in children,adults,and the elderly.However,given the low methodological quality and the level of evidence from systematic reviews/meta-analyses,further high-quality research is required to validate these results.
Neuraminidase inhibitorInfluenzaumbrella reviewOverviews of systematic reviews
万方数据
维普
